Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 16Recruiting 9Unknown 6Withdrawn 3Terminated 2Not yet recruiting 2Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Hematologic Neoplasms 2Pain 1Neoplasms, Germ Cell and Embryonal 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × OTHER × Olanzapine × Clear all
NCT05403580 2024-05-06

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer

Mayo Clinic

Phase 3 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

NCT03960151 2019-05-22

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

Hoosier Cancer Research Network

Phase 2 Withdrawn

Neoplasms, Germ Cell and Embryonal

NCT00737191 2012-03-09

Opioids With or Without Olanzapine in Treating Patients With Moderate to Severe Cancer Pain

Mayo Clinic

Phase NA Withdrawn
Other hematologic neoplasm

Pain, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡